{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:24:17Z","timestamp":1759667057211},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,4,7]]},"DOI":"10.18632\/oncotarget.27530","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T16:06:51Z","timestamp":1586275611000},"page":"1235-1243","source":"Crossref","is-referenced-by-count":5,"title":["A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies"],"prefix":"10.18632","volume":"11","author":[{"given":"Matthew H.","family":"Taylor","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajjai S.","family":"Alva","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Larson","sequence":"additional","affiliation":[{"name":"USOR \u2013 Minnesota Oncology, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Szpakowski","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Das","family":"Purkaystha","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpesh","family":"Amin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Karpiak","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK signaling pathways in cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Lovly","year":"2018","journal-title":"Mol Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Heinrich","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tgh.2018.01.02","article-title":"Molecular characterization and pathogenesis of gastrointestinal stromal tumor","volume":"3","author":"Sugai","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Kurzrock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Stewart","year":"2005","journal-title":"Blood"},{"key":"7","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","article-title":"CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia","volume":"11","author":"Heise","year":"2005","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Heise","year":"2005","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/bjc.2017.290","article-title":"Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib","volume":"117","author":"Bauer","year":"2017","journal-title":"Br J Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.2147\/CMAR.S176172","article-title":"Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis","volume":"10","author":"Sun","year":"2018","journal-title":"Cancer Manag Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"21383","DOI":"10.18632\/oncotarget.25109","article-title":"Signature program: a platform of basket trials","volume":"9","author":"Salvado","year":"2018","journal-title":"Oncotarget"},{"key":"12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Brennan","year":"2013","journal-title":"Nat Biotechnol"},{"key":"15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/01621459.1995.10476550","article-title":"Bayesian density estimation and inference using mixtures","volume":"90","author":"West","year":"1995","journal-title":"J Am Stat Assoc"},{"key":"16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1740774513497539","article-title":"Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials","volume":"10","author":"Berry","year":"2013","journal-title":"Clin Trials"},{"key":"17","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ejca.2015.05.020","article-title":"An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer","volume":"51","author":"Cho","year":"2015","journal-title":"Eur J Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy","volume":"19","author":"Deudon","year":"2017","journal-title":"Breast Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1373\/clinchem.2015.247882","article-title":"The use of targeted therapies for precision medicine in oncology","volume":"62","author":"Kamel-Reid","year":"2016","journal-title":"Clin Chem"},{"key":"20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/annonc\/mdx098","article-title":"Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma","volume":"28","author":"Yun","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T20:51:24Z","timestamp":1591390284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":20,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,4,7]]}},"alternative-id":["27530","32292573"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27530","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}